Skip to main content
  • Research article
  • Open access
  • Published:

Quality of diabetes care in patients with schizophrenia: a case-control study in Qatar



Patients with schizophrenia are at least twice as likely to develop diabetes mellitus compared to the general population. This is of significance in Qatar given the high prevalence of obesity and diabetes. Furthermore, the lifespan of people with schizophrenia is shortened by approximately 15 years, partly due to long-term microvascular and macrovascular complications. High quality diabetes care can significantly reduce morbidity and mortality. We assessed the level of diabetes care delivered to patients in Qatar with schizophrenia and diabetes compared to those with diabetes alone.


We performed a retrospective chart review of patients with diabetes mellitus with (n = 73) and without (n = 73) schizophrenia. Demographic information and electronic medical records were reviewed to determine adherence to American Diabetes Association standards of diabetes care in the last 6 and 12 months. Optimal diabetes care was defined as having completed glycated hemoglobin (HbA1c), lipid profile and retinal examination within 12 months.


Optimal diabetes care was significantly lower in patients with schizophrenia and diabetes compared to diabetes alone [26.0% (n = 19/73) vs 52.1% (n = 38/73), p = 0.002]. Patients with diabetes and schizophrenia were also significantly less likely to have had body mass index recorded within 6 months (p = 0.008) and HbA1c (p = 0.006), lipid profile (p = 0.015), estimated glomerular filtration rate (eGFR) (p = 0.001) and order for retinal examination (p = 0.004) over 12 months. After adjusting for multiple comparisons, only assessment of eGFR (p = 0.01) and order for retinal examination (p = 0.04) remained significant.


Patients in Qatar with schizophrenia and diabetes, receive sub-optimal diabetes care compared to those with diabetes alone.

Peer Review reports


Diabetes Mellitus (DM) has an estimated global prevalence of 8.5% in the adult population [1]. Qatar, Kuwait, and Saudi Arabia in the Middle East and North Africa Region (MENA) are three of the top 10 countries with the highest diabetes prevalence worldwide [2]. In Qatar, 70.1% of Qatari nationals are clinically overweight (Body Mass Index (BMI) ≥25 kg/m2), and 41.4% obese (BMI ≥30 kg/m2) [3]. The prevalence of diabetes in people with schizophrenia is estimated to be 2 to 3 times higher compared to the general population [4], with over four-fold increased odds of comorbid diabetes in patients with non-affective psychosis and a family history of type II DM [5]. The high prevalence of diabetes in people with schizophrenia reflects multiple factors including a more sedentary lifestyle, higher prevalence of obesity, poorer diet, metabolic side effects of antipsychotic medication and possibly intrinsic factors including genetic predisposition and inflammation [6].

Dysglycemia is also associated with the severity of schizophrenia, particularly negative symptoms and cognitive impairment [7]. A large Danish cohort study investigated diabetes development in antipsychotic-naïve schizophrenia patients [8]. Diabetes was associated with well recognized diabetes risk factors, including higher age, and treatment with a range of antipsychotic drugs. A cross-sectional study in Qatar reported a higher prevalence of metabolic syndrome among psychiatric patients taking antipsychotics versus a control group without psychiatric illness, but the difference did not reach statistical significance (31.9% vs 22.8%, p = 0.12) [9]. Most patients in this study were taking second generation antipsychotics and were diagnosed with schizophrenia, schizoaffective disorder or bipolar affective disorder [9]. All-cause mortality for people with schizophrenia is significantly increased, with a recent longitudinal study in the United States showing an all-cause standardized mortality ratio of 3.7 (95% CI, 3.7–3.7) [10]. The lifespan of patients with schizophrenia is shortened by approximately 15 years with the largest single cause of death being cardiovascular disease [11]. Provision of high-quality diabetes care, particularly the management of cardiovascular risk factors, could reduce this elevated mortality and healthcare costs for providers.

Delivering optimal diabetes care in patients with schizophrenia can be challenging as patient, provider, treatment and system-level factors may act as barriers to following evidence-based guidelines [12]. Data on rates of engagement with primary care appointments for patients with schizophrenia are conflicting. A study from Norway found that patients diagnosed with schizophrenia regularly consulted their general practitioner [13] and a cohort study using Danish nationwide registry data showed that people with schizophrenia consulted primary care more frequently compared to age and gender matched controls [14]. However, those with schizophrenia with comorbid medical illnesses had a higher relative risk of not following up with their clinical appointments, 5 years after the index diagnosis [14]. Furthermore, a study from the United States in subjects with diabetes and comorbid psychiatric disorders found that a diagnosis of either bipolar disorder or schizophrenia (versus depression) was significantly associated with decreased appointment attendance [15]. Although, after multivariate analysis and adjustment, only bipolar disorder remained associated with reduced clinic attendance [15]. 

Several studies have reported that patients with DM and serious mental illness (SMI) are less likely to receive optimal diabetes care [12, 15,16,17]. In Canada, Kurdyak et al. (2017) showed that schizophrenia was associated with a reduced likelihood of optimal diabetes care (HbA1c, lipid profile and retinal examination) over the preceding 2 years [adjusted odds ratio (OR) (95% CI): 0.64 (0.61–0.67)] and an increased likelihood of diabetes-related emergency department (ED) visits (adjusted OR (95% CI): 1.34 (1.28–1.41)) and hospitalization (adjusted OR (95% CI): 1.36 (1.28–1.43)) [12]. These results are consistent with an earlier study showing an increased rate of diabetes-related emergency department visits in people with schizophrenia (Hazard Ratio = 1.74, 95% CI (1.42–2.12)) [18]. Indeed, the non-treatment rates for diabetes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study in patients with schizophrenia was 45.3% [19]. However, a study by Whyte et al in 2007 found that the quality of diabetes care in the United Kingdom was comparable between patients with schizophrenia or bipolar disorder with comorbid diabetes and those with diabetes alone [20]. This contrasting result may reflect the fact that Whyte et al. examined the quality of diabetes care in the first year following the introduction of a new government contract for primary care doctors which offered financial incentives if specific targets were met. These included 17 quality indicators for diabetes care. Indeed, engagement with mental health services and adherence to antipsychotic treatment is associated with a significant reduction in diabetes related hospitalization [21]. An association has also been found between more frequent outpatient psychiatry (OR = 1.28, 95% CI = 1.20–1.37) and primary care (OR = 2.10, 95% CI = 1.85–2.39) visits and optimal diabetes testing [22].

The quality of diabetes care received by people with schizophrenia in Qatar has not been investigated previously. This is of relevance given the high prevalence of obesity and diabetes in Qatar. Our aim was to determine the quality of diabetes care in patients with schizophrenia and diabetes compared to patients with diabetes alone.



Qatar is situated on the west coast of the Persian Gulf. Nearly 90% of the country’s population of 2.9 million people are expatriate workers. Most of the population live in Doha, the capital. The median age is 32 years. Hamad Medical Corporation (HMC) and the Primary Health Care Corporation (PHCC) are the main providers of free or subsidized governmental healthcare services in The State of Qatar. HMC provides comprehensive secondary and tertiary level care that includes mental health outpatient clinics and diabetes clinics as well as inpatient care. The PHCC provides primary care services via modern primary care health centers. Electronic Medical Records (EMRs) include a list of all encounters within HMC and PHCC for each patient. Our population of interest included all patients being followed up with mental health outpatient services and/or the diabetes clinic at HMC.

Period of study

Data were extracted retrospectively from EMRs between January and December of 2018.

Eligible population and sample

We identified two cohorts of patients on the CERNER Electronic Medical Records (EMRs) system in outpatient clinics in Hamad Medical Corporation (HMC), Doha, Qatar: those with diabetes and schizophrenia (study group) and those with diabetes and no serious psychiatric illness (control group). Cohorts were limited to subjects 18 years of age and older. Both genders and all nationalities were included. Diagnoses of both diabetes and schizophrenia were based on documentation on EMRs. Standards of diabetes care were retrospectively recorded for the year 2018, and patients were only included if they were diagnosed with both DM and schizophrenia prior to 2018. Patients were assigned subject numbers and selected using a random number generator.

Variables included

Based on recommendations by the American Diabetes Association (ADA) [23], we used the completion of the following as indices of optimal diabetes care: HbA1c, BMI and blood pressure over 6 months (July through December 2018) and HbA1c, BMI, blood pressure, lipid profile, retinal examination, foot examination, serum creatinine and eGFR over 12 months (January through December of 2018). In addition to the ADA key measures of optimal diabetes care, we added referrals to the dietician and diabetes educators as two additional indices since these are recommended by the local guidelines and are key to the implementation of changes to the management of patients with diabetes. We also recorded the total number of medical and psychiatric admissions over 12 months.

To define optimal diabetes care as a binary variable, we chose the completion of HbA1c, lipid profile, and retinal examination within 12 months. This definition was used in a previous study by Kurdyak et al [12].

Data sources

Patient demographics, encounters with different facilities and specialties, in addition to investigations, diagnostic and therapeutic procedures are all currently available on EMRs. We extracted sociodemographic and clinical data from EMRs and recoded the data in a computerized data base for analysis.

Sample size calculation

A previous study showed that the rate of HbA1c testing in patients with schizophrenia and DM was significantly lower compared to patients with diabetes alone (48% vs 71%, p = .0001) [24]. Using the same proportions, with an alpha = 0.05, power = 0.9, and sample size distribution ratio of 1:1, the calculated sample size in each group was 73, with a total sample size of 146 [25].

Statistical analysis

Statistical analysis was conducted using the Statistical Package for the Social Sciences (IBM-SPSS, version 23.0, IBM Corp, Armonk, NY, USA). For categorical variables, we calculated the frequency. For continuous variables, we calculated the mean and standard deviation (SD). The differences between the study and control groups were analyzed using Pearson’s chi-squared test for categorical variables (and in case of non-validity, the Fishers’ exact test), and t-test for continuous variables. For multiple comparisons, p values were adjusted using the Holm Bonferroni method.

Ethical issues

The study was approved by the Medical Research Center (MRC) and Institutional Review Board (IRB). The IRB confirmed that patient consent was not required as the data was obtained from existing medical records. The study complied with all HMC research governance protocols.


Sociodemographic and clinical characteristics of the groups

The study assessed participants with schizophrenia and diabetes (n = 73) versus those with diabetes only (n = 73). Participants with diabetes and schizophrenia were significantly younger compared to the control group (45.1 ± 13.0 vs 57.9 ± 11.1; p < 0.001). There was no significant difference between the two groups in terms of gender, nationality, BMI, HbA1c and the number of admissions (medical and psychiatric combined) (Table 1).

Table 1 Sociodemographic and clinical characteristics of patients with diabetes vs patients with diabetes and schizophrenia

Standards of optimal diabetes care

Five standards were significantly less likely to be met in patients with diabetes and schizophrenia compared to diabetes alone: BMI recorded within 6 months (p = 0.008) and HbA1c (p = 0.006), lipid profile (p = 0.015), eGFR (p = 0.001) and order for retinal examination over 12 months (p = 0.004). However, after adjusting for multiple comparisons, only assessment of eGFR (p = 0.01) and order for retinal examination (p = 0.04) within the last 12 months remained significant (Table 2). Using the three-item binary definition of optimal diabetes care (HbA1c, lipid profile and retinal examination over 12 months), patients with diabetes and schizophrenia were less likely to receive optimal diabetes care compared to those with diabetes alone [26.0% (n = 19/73) vs 52.1% (n = 38/73), p = 0.002].

Table 2 Standards of optimal diabetes care and monitoring in patients with diabetes vs patients with diabetes and schizophrenia


After controlling for multiple testing, we found that patients with diabetes and schizophrenia were significantly less likely to meet 2 ADA standards of diabetic care compared to patients with diabetes alone. These were assessment of eGFR and order for retinal screening examination within the last 12 months. Using the three-item definition of optimal diabetes care (HbA1c, lipid profile and retinal examination over 12 months), patients with diabetes and schizophrenia were half as likely to receive optimal diabetes care compared to those with diabetes alone. A Canadian study using the same definition over 2 years reported very similar findings [12]. Our findings are consistent with a series of previous studies wherein patients with schizophrenia are less likely to receive high quality diabetes care [15,16,17].

Suboptimal diabetes care in our study group may be attributed to a lack of integrated physical and mental health services and difficulty sharing information and expertise amongst health care specialties [26]. Stigma and lack of training for non-psychiatric physicians on the physical and mental health care needs for people with SMI might further hinder optimal health care delivery. Magliano el al (2017) found that general practitioners (GPs) perceived patients with schizophrenia as dangerous, less likely to recover, and in need of long-term pharmacotherapy [27]. Fleury et al. (2012) found that GPs in Quebec regarded themselves as competent managing common but not serious mental health problems. Over half of participating GPs reported no contact with mental health resources, and most regarded the mental health system to be of poor quality, particularly in terms of accessibility and availability of services [28]. Symptoms of schizophrenia, including psychotic symptoms, negative symptoms, cognitive deficits and impaired insight have been implicated in poor adherence to medication [29] and clinic appointments. Schizophrenia is also frequently comorbid with depression and substance misuse [30], which can further hinder engagement with diabetes care. Socioeconomic status is unlikely to affect the quality of care in Qatar, as health care services are mostly free of charge for citizens and provided with minimal charge for residents of the country.

In our sample, patients with diabetes alone were significantly older compared to those with both diabetes and schizophrenia, which could reflect the earlier onset of diabetes due to lifestyle and medications used for schizophrenia [8]. However, the level of obesity (BMI) and glycemic control (HbA1c) was comparable between the two groups. A recent study in Qatar also found no significant difference in central obesity or the prevalence of metabolic syndrome between patients receiving antipsychotics and controls [9]. The prevalence of obesity, metabolic syndrome, and glucose abnormalities was high in both groups. This possibly indicates either a type II error or the fact that the high prevalence of obesity and metabolic syndrome among the general Qatari population might have masked any further effect of antipsychotics or schizophrenia on these outcomes.

We propose several strategies to reduce the inequalities reported. Educational awareness programs for health professionals are needed to address mental health stigma and negative stereotypes. Further work is required to increase awareness amongst HCPs regarding the increased morbidity and mortality in patients with schizophrenia. Communication between different services providing health care for patients with schizophrenia is essential to ensuring access to health care services and optimizing management of medical comorbidities. Education to prevent or limit obesity and diabetes needs to be promoted among patients with severe mental illness to help decrease the prevalence of diabetes and ensure that those diagnosed with diabetes receive high quality care. These recommendations are in line with the recently published blueprint for protecting physical health in people with mental illness [31].

Strengths and limitations

This population-based study included randomly assigned patients from both genders and all nationalities followed in outpatient clinics. Data to identify and control for the duration of diabetes and schizophrenia in our cohorts was limited as the EMRs system was started in 2015. Additionally, important demographic information such as smoking, marital and socioeconomic status were missing or inconsistently documented. Nevertheless, lab results, orders and documentation pertaining to diabetes care were easily extractible, and the criteria for optimal diabetes care were clearly defined. As this is a case-control study, the incidence and relative risk of suboptimal diabetes care in patients with schizophrenia could not be calculated.


This study found that patients with schizophrenia and diabetes in Qatar are less likely to receive optimal diabetes care compared to patients with diabetes alone, particularly in relation to the assessment of microvascular complications with a decreased frequency of eGFR assessment and request for retinal examination. These data demand further larger population cohort studies to assess adherence with treatment and the burden of diabetes-related medical comorbidities and complications in patients with schizophrenia.

Availability of data and materials

The data that support the findings of this study are available from the corresponding author upon reasonable request and pending additional ethical approval.



American Diabetes Association


Body-Mass Index


Clinical Antipsychotic Trials of Intervention Effectiveness


Cardiovascular Disease


Confidence Interval


Diabetes Mellitus


Emergency Department


Estimated Glomerular Filtration Rate


Electronic Medical Records


General Practitioners


Glycosylated Hemoglobin


Health Care Professionals


Hamad Medical Corporation


Institutional Review Board


Middle East and North Africa


Odds Ratio


Serious Mental Illness


  1. Sarwar N, Gao P, Kondapally Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–22.

    Article  CAS  Google Scholar 

  2. Aguiree F, Brown A, Cho NH, Dahlquist G, Dodd S, Dunning T, Hirst M, Hwang C, Magliano D, Patterson C, Scott C, Shaw J, Soltesz G, Usher-Smith JWD. International diabetes federation. IDF diabetes atlas. 6th ed. Brussels: International Diabetes Federation; 2013.

  3. Haj Bakri A, Al-Thani A. Chronic disease risk factor surveillance: Qatar STEPS report 2012. Doha: The Supreme Council of Health; 2013.

  4. De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al.  Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52–77.

  5. Chung J, Miller BJ. Meta-analysis of comorbid diabetes and family history of diabetes in non-affective psychosis. Schizophr Res. 2020;216:41–7.

  6. Hoffman R. The complex inter-relationship between diabetes and schizophrenia. Curr Diabetes Rev. 2017;13(3):528–32.

    PubMed  Google Scholar 

  7. Perry BI, Salimkumar D, Green D, Meakin A, Gibson A, Mahajan D, et al. Associated illness severity in schizophrenia and diabetes mellitus: a systematic review. Psychiatry Res. 2017;256:102–10.

  8. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology. 2010;35(9):1997–2004.

  9. Hammoudeh S, Ghuloum S, Mahfoud Z, Yehya A, Abdulhakam A, Al-Mujalli A, et al. The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study. BMC Psychiatry. 2018;18(1):81.

  10. Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry. 2015;72(12):1172–81.

    Article  Google Scholar 

  11. Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017;4(4):295–301.

    Article  Google Scholar 

  12. Kurdyak P, Vigod S, Duchen R, Jacob B, Stukel T, Kiran T. Diabetes quality of care and outcomes: comparison of individuals with and without schizophrenia. Gen Hosp Psychiatry. 2017;46:7–13.

  13.  Hetlevik Ø, Solheim M, Gjesdal S. Use of GP services by patients with schizophrenia: a national cross-sectional register-based study. BMC Health Serv Res. 2015;15:66.

  14. Nørgaard HCB, Schou Pedersen H, Fenger-Grøn M, Vestergaard M, Nordentoft M, Laursen TM, et al. Schizophrenia and attendance in primary healthcare: a population-based matched cohort study. Scand J Prim Health Care. 2019;37(3):358–65.

  15. Frayne SM, Halanych JH, Miller DR, Wang F, Lin H, Pogach L, et al. Disparities in diabetes care: impact of mental illness. Arch Intern Med. 2005;165(22):2631–8.

    Article  Google Scholar 

  16. Jørgensen M, Mainz J, Carinci F, Thomsen RW, Johnsen SP. Quality and predictors of diabetes care among patients with schizophrenia: a Danish nationwide study. Psychiatr Serv. 2018;69(2):179–85.

  17. Druss BG, Zhao L, Cummings JR, Shim RS, Rust GS, Marcus SC. Mental comorbidity and quality of diabetes care under medicaid: a 50-state analysis. Med Care. 2012;50(5):428–33.

    Article  Google Scholar 

  18. Becker T, Hux J. Risk of acute complications of diabetes among people with schizophrenia in Ontario, Canada. Diabetes Care. 2011;34(2):398–402.

    Article  Google Scholar 

  19. Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006;86(1–3):15–22.

    Article  Google Scholar 

  20. Whyte S, Penny C, Phelan M, Hippisley-Cox J, Majeed A. Quality of diabetes care in patients with schizophrenia and bipolar disorder: cross-sectional study. Diabet Med. 2007;24:1442–8.

    Article  CAS  Google Scholar 

  21. Egglefield K, Cogan L, Leckman-Westin E, Finnerty M. Antipsychotic medication adherence and diabetes-related hospitalizations among medicaid recipients with diabetes and schizophrenia. Psychiatr Serv. 2020;71(3):236–42.

  22. Hsu JH, Calzavara A, Vigod S, Stukel TA, Kiran T, Kurdyak P. Factors associated with diabetes care quality among patients with schizophrenia in Ontario, Canada. Psychiatr Serv. 2020;71(2):188–91.

  23. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2018;41(Suppl 1). Available from:

  24. O’Connor PJ, Crain AL, Rush WA, et al. Impact of schizophrenia diagnosis on diabetes care in adults. American Diabetes Association. Abstract Number 2807-PO. Available from: Accessed 2 Feb 2021.

  25. Kelsey JL, Whittemore AS, Evans AS, Thompson WD. Methods in observational epidemiology. 2nd ed. New York: Oxford University Press; 1996.

  26. Druss BG. Improving medical care for persons with serious mental illness: challenges and solutions. J Clin Psychiatry. 2007;68(Suppl 4):40–4.

  27. Magliano L, Strino A, Punzo R, Acone R, Affuso G, Read J. Effects of the diagnostic label 'schizophrenia', actively used or passively accepted, on general practitioners' views of this disorder. Int J Soc Psychiatry. 2017;63(3):224–34.

  28. Fleury M-J, Farand L, Aubé D, Imboua A. Management of mental health problems by general practitioners in Quebec. Can Fam Physician. 2012;58(12).

  29. Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014;5:43–62.

  30. Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009;35(2):383–402.

  31. Firth J, Siddiqi N, Koyanagi A, Siskind D, Rosenbaum S, Galletly C, et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry. 2019;6:675–712.

Download references


Not applicable.


The project received no funding from any governmental or private institution.

Author information

Authors and Affiliations



PMH and MAK conceived the idea for the study and together with PW, RAM and ZD designed the protocol. MAK, NA, AK, AHA, AA, and MZ collected the data. MAK and SO conducted the statistical analysis. All authors contributed to writing and revising the paper and approved the final version.

Corresponding author

Correspondence to Peter M. Haddad.

Ethics declarations

Ethics approval and consent to participate

The study proposal was approved by the Medical Research Center (MRC) and Institutional Review Board (IRB) at HMC (proposal ID: MRC-01-19-051). The IRB confirmed that patient consent was not required as the data used in the study was obtained from existing medical records. All necessary administrative approvals were obtained to access the data and the study was conducted in accordance with the HMC research governance framework.

Consent for publication

Not applicable.

Competing interests

In the last 3 years, PMH reports personal fees from Janssen, Lundbeck, Otsuka, NewBridge Pharmaceuticals and Sunovion, outside the submitted work. RAM reports personal fees for educational lectures from Novo Nordisk, Pfizer, Lilly and Proctor and Gamble. The other authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Karim, M.A., Al-Baz, N., Ouanes, S. et al. Quality of diabetes care in patients with schizophrenia: a case-control study in Qatar. BMC Psychiatry 21, 149 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: